Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | UNG | P13051 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19249007 | 0.83 | POLB (0.48) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL3763507 | 0.81 | VSIR (0.53) | FPR3FPR2VSIRMAPTCA12 | |
| SCHEMBL12121617 | 0.81 | MAPT (0.55) | MAPTMEN1HTTKMT2AALDH1A1 | |
| SCHEMBL2655145 | 0.80 | MEN1 (0.46) | MAPTCA1CA2PTPRCMEN1 | |
| SCHEMBL4119738 | 0.80 | ALDH1A1 (0.47) | FPR3FPR2VSIRMAPTCA12 | |
| SCHEMBL14065391 | 0.80 | HDAC3 (0.46) | FPR3FPR2VSIRMAPTCA12 | |
| SCHEMBL1433839 | 0.80 | MEN1 (0.47) | FPR3FPR2MAPTCA12CA1 | |
| SCHEMBL30936914 | 0.80 | FPR3 (0.48) | FPR3FPR2MAPTCA12CA1 | |
| SCHEMBL9132938 | 0.80 | MAPT (0.46) | FPR3FPR2VSIRMAPTMEN1 | |
| SCHEMBL20798155 | 0.79 | FPR3 (0.48) | FPR3FPR2MAPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585517-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004062663-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | FPR3 231/4885FPR2 200/4885VSIR 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.